<p>随着美国股市持续攀升，纳斯达克和标准普尔 500 等指数创下新高，投资者正在探索市场不同领域的各种机会。便士股票，这个可能显得过时但仍然重要的术语，代表着较小或不太成熟的公司，可能提供潜在的价值。通过关注那些财务稳健且具有增长潜力的公司，投资者可能会在这些鲜为人知的股票中发现有前景的机会。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器中的 362 只股票的完整列表。</p>
<p>在这里，我们突出显示了我们筛选器中首选股票的一个子集。</p>
<h2>Rapid Micro Biosystems (RPID)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Rapid Micro Biosystems, Inc. 是一家生命科学技术公司，提供用于检测制药、医疗设备和个人护理产品制造中微生物污染的产品，市值为 1.6756 亿美元，覆盖多个国际市场。</p>
<p><strong>运营：</strong> 该公司主要通过系统及相关的 LIMS 连接软件、耗材和服务产生收入，总计 3029 万美元。</p>
<p><strong>市值：</strong> 1.6756 亿美元</p>
<p>Rapid Micro Biosystems, Inc. 以 1.6756 亿美元的市值在便士股票的挑战性环境中，专注于收入增长和财务稳定。尽管公司处于亏损状态，股本回报率为负，但其收入持续增长，2025 年上半年报告收入为 1447 万美元，而 2024 年为 1223 万美元。公司无债务，并且最近获得了 4500 万美元的贷款，以支持其全球扩张和提高制造效率。管理团队经验丰富，短期负债由价值 6010 万美元的资产充分覆盖。</p>
<ul>
<li>点击探索我们在 Rapid Micro Biosystems 财务健康报告中的详细发现。</li>
<li>通过访问我们的收益增长报告评估 Rapid Micro Biosystems 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 10 月的 RPID 债务与股本历史及分析</p>
<h2>Nuvation Bio (NUVB)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Nuvation Bio Inc. 是一家临床阶段的生物制药公司，开发用于肿瘤学的治疗候选药物，市值约为 12.7 亿美元。</p>
<p><strong>运营：</strong> Nuvation Bio 的收入主要来自其肿瘤学开发活动，总计 1436 万美元。</p>
<p><strong>市值：</strong> 12.7 亿美元</p>
<p>Nuvation Bio Inc. 是一家市值为 12.7 亿美元的临床阶段生物制药公司，正在通过推进其肿瘤学管线，特别是 IBTROZI™（taletrectinib），在便士股票市场中寻求发展。最近获得日本 MHLW 和美国 FDA 的批准，突显其在治疗 ROS1 阳性非小细胞肺癌方面的潜力。尽管公司处于亏损状态，2025 年上半年报告收入为 792 万美元，且流动性强，短期资产显著超过负债。公司现金多于债务，但面临高波动性和董事会经验不足等挑战。</p>
<ul>
<li>解锁我们对 Nuvation Bio 股票分析的全面见解，查看此财务健康报告。</li>
<li>通过我们的详细增长报告评估 Nuvation Bio 未来的收益预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis"/></p>
<p>截至 2025 年 10 月的 NUVB 财务状况分析</p>
<h2>Waterdrop (WDH)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Waterdrop Inc. 在中国作为在线保险经纪公司运营，连接用户与保险产品，市值约为 7.0524 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其保险业务，产生了 28.78 亿人民币，此外还有 1536.8 万人民币来自众筹活动。</p>
<p><strong>市值：</strong> 7.0524 亿美元</p>
<p>Waterdrop Inc. 在便士股票领域表现出强劲的财务表现，市值约为 7.0524 亿美元。公司报告了显著的收益增长，2025 年第二季度净收入上升至 1.4016 亿人民币，较去年同期的 8829 万人民币有所增加。其短期资产（40 亿人民币）轻松覆盖负债，并且通过现金多于债务保持强劲的流动性。尽管交易价格低于其估计的公允价值，并且拥有高质量的收益，Waterdrop 的股本回报率仍然较低，为 8.6%。最近的战略举措包括价值 5000 万美元的股票回购计划和增强股东价值的股息确认。</p>
<ul>
<li>在我们的财务健康报告中更深入地了解 Waterdrop 的潜力。</li>
<li>检查 Waterdrop 的收益增长报告，以了解分析师对其表现的预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis"/></p>
<p>WDH 财务状况分析截至 2025 年 10 月</p>
<h2>利用机会</h2>
<ul>
<li>通过在这里使用我们的筛选器，深入了解所有 362 只美国便士股票。</li>
<li>寻找新的视角？癌症的终结？这 28 只新兴 AI 股票正在开发技术，以便早期识别改变生命的疾病，如癌症和阿尔茨海默病。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

水滴

RPID

NUVB

<p>随着美国股市的上涨，投资者开始关注低价股的潜在价值。值得一提的是 Rapid Micro Biosystems（RPID），这是一家市值为 1.6756 亿美元的生命科学技术公司，专注于微生物污染检测。尽管尚未盈利，但该公司报告了收入增长，并获得了 4500 万美元的贷款用于扩张。Nuvation Bio（NUVB）是一家市值为 12.7 亿美元的生物制药公司，正在推进其肿瘤学产品线。水滴（WDH）是一家中国的在线保险经纪公司，显示出强劲的盈利增长，并保持良好的流动性</p>

<p>As the U.S. stock market continues to climb, with indices like the Nasdaq and S&amp;P 500 reaching new highs, investors are exploring various opportunities in different segments of the market. Penny stocks, a term that may seem outdated yet remains significant, represent smaller or less-established companies that can offer potential value. By focusing on those with solid financials and growth potential, investors might uncover promising opportunities among these lesser-known stocks.</p>
<div class="lb-trans"><p>随着美国股市持续攀升，纳斯达克和标准普尔 500 等指数创下新高，投资者正在探索市场不同领域的各种机会。便士股票，这个可能显得过时但仍然重要的术语，代表着较小或不太成熟的公司，可能提供潜在的价值。通过关注那些财务稳健且具有增长潜力的公司，投资者可能会在这些鲜为人知的股票中发现有前景的机会。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 362 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器中的 362 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出显示了我们筛选器中首选股票的一个子集。</p>
</div><h2>Rapid Micro Biosystems (RPID)</h2>
<div class="lb-trans"><h2>Rapid Micro Biosystems (RPID)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Rapid Micro Biosystems, Inc. is a life sciences technology company that offers products for detecting microbial contamination in the manufacturing of pharmaceuticals, medical devices, and personal care products across various international markets, with a market cap of $167.56 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Rapid Micro Biosystems, Inc. 是一家生命科学技术公司，提供用于检测制药、医疗设备和个人护理产品制造中微生物污染的产品，市值为 1.6756 亿美元，覆盖多个国际市场。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from Systems and Related LIMS Connection Software, Consumables, and Services, totaling $30.29 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过系统及相关的 LIMS 连接软件、耗材和服务产生收入，总计 3029 万美元。</p>
</div><p><strong>Market Cap:</strong> $167.56M</p>
<div class="lb-trans"><p><strong>市值：</strong> 1.6756 亿美元</p>
</div><p>Rapid Micro Biosystems, Inc., with a market cap of US$167.56 million, is navigating the challenging landscape of penny stocks by focusing on revenue growth and financial stability. Despite being unprofitable with a negative return on equity, the company has shown consistent revenue increases, reporting US$14.47 million for the first half of 2025 compared to US$12.23 million in 2024. It remains debt-free and has recently secured a US$45 million loan facility to support its global expansion efforts and enhance manufacturing efficiencies. The management team is experienced, and short-term liabilities are well-covered by assets worth US$60.1 million.</p>
<div class="lb-trans"><p>Rapid Micro Biosystems, Inc. 以 1.6756 亿美元的市值在便士股票的挑战性环境中，专注于收入增长和财务稳定。尽管公司处于亏损状态，股本回报率为负，但其收入持续增长，2025 年上半年报告收入为 1447 万美元，而 2024 年为 1223 万美元。公司无债务，并且最近获得了 4500 万美元的贷款，以支持其全球扩张和提高制造效率。管理团队经验丰富，短期负债由价值 6010 万美元的资产充分覆盖。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Rapid Micro Biosystems' financial health report.</li>
<li>Evaluate Rapid Micro Biosystems' prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Rapid Micro Biosystems 财务健康报告中的详细发现。</li>
<li>通过访问我们的收益增长报告评估 Rapid Micro Biosystems 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis"/></p>
<p>RPID Debt to Equity History and Analysis as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 RPID 债务与股本历史及分析</p>
</div><h2>Nuvation Bio (NUVB)</h2>
<div class="lb-trans"><h2>Nuvation Bio (NUVB)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology, with a market cap of approximately $1.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nuvation Bio Inc. 是一家临床阶段的生物制药公司，开发用于肿瘤学的治疗候选药物，市值约为 12.7 亿美元。</p>
</div><p><strong>Operations:</strong> Nuvation Bio generates revenue from its oncology development activities, totaling $14.36 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Nuvation Bio 的收入主要来自其肿瘤学开发活动，总计 1436 万美元。</p>
</div><p><strong>Market Cap:</strong> $1.27B</p>
<div class="lb-trans"><p><strong>市值：</strong> 12.7 亿美元</p>
</div><p>Nuvation Bio Inc., a clinical-stage biopharmaceutical company with a market cap of US$1.27 billion, is navigating the penny stock landscape by advancing its oncology pipeline, particularly with IBTROZI™ (taletrectinib). Recent approvals from Japan's MHLW and the U.S. FDA highlight its potential in treating ROS1-positive non-small cell lung cancer. Despite being unprofitable, Nuvation Bio reported US$7.92 million in revenue for the first half of 2025 and maintains strong liquidity with short-term assets exceeding liabilities significantly. The company has more cash than debt but faces challenges like high volatility and an inexperienced board of directors.</p>
<div class="lb-trans"><p>Nuvation Bio Inc. 是一家市值为 12.7 亿美元的临床阶段生物制药公司，正在通过推进其肿瘤学管线，特别是 IBTROZI™（taletrectinib），在便士股票市场中寻求发展。最近获得日本 MHLW 和美国 FDA 的批准，突显其在治疗 ROS1 阳性非小细胞肺癌方面的潜力。尽管公司处于亏损状态，2025 年上半年报告收入为 792 万美元，且流动性强，短期资产显著超过负债。公司现金多于债务，但面临高波动性和董事会经验不足等挑战。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Nuvation Bio stock in this financial health report.</li>
<li>Assess Nuvation Bio's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Nuvation Bio 股票分析的全面见解，查看此财务健康报告。</li>
<li>通过我们的详细增长报告评估 Nuvation Bio 未来的收益预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis"/></p>
<p>NUVB Financial Position Analysis as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 NUVB 财务状况分析</p>
</div><h2>Waterdrop (WDH)</h2>
<div class="lb-trans"><h2>Waterdrop (WDH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Waterdrop Inc. operates as an online insurance brokerage in China, connecting users with insurance products, and has a market cap of approximately $705.24 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Waterdrop Inc. 在中国作为在线保险经纪公司运营，连接用户与保险产品，市值约为 7.0524 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its insurance segment, which generated CN¥2.78 billion, complemented by CN¥153.68 million from crowd funding activities.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其保险业务，产生了 28.78 亿人民币，此外还有 1536.8 万人民币来自众筹活动。</p>
</div><p><strong>Market Cap:</strong> $705.24M</p>
<div class="lb-trans"><p><strong>市值：</strong> 7.0524 亿美元</p>
</div><p>Waterdrop Inc., with a market cap of approximately US$705.24 million, has shown robust financial performance in the penny stock arena. The company reported significant earnings growth, with net income rising to CN¥140.16 million for Q2 2025, up from CN¥88.29 million a year ago. Its short-term assets (CN¥4 billion) comfortably cover liabilities, and it maintains strong liquidity by having more cash than debt. Despite trading below its estimated fair value and boasting high-quality earnings, Waterdrop's return on equity remains low at 8.6%. Recent strategic moves include a share repurchase program worth US$50 million and dividend affirmations enhancing shareholder value.</p>
<div class="lb-trans"><p>Waterdrop Inc. 在便士股票领域表现出强劲的财务表现，市值约为 7.0524 亿美元。公司报告了显著的收益增长，2025 年第二季度净收入上升至 1.4016 亿人民币，较去年同期的 8829 万人民币有所增加。其短期资产（40 亿人民币）轻松覆盖负债，并且通过现金多于债务保持强劲的流动性。尽管交易价格低于其估计的公允价值，并且拥有高质量的收益，Waterdrop 的股本回报率仍然较低，为 8.6%。最近的战略举措包括价值 5000 万美元的股票回购计划和增强股东价值的股息确认。</p>
</div><ul>
<li>Take a closer look at Waterdrop's potential here in our financial health report.</li>
<li>Examine Waterdrop's earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更深入地了解 Waterdrop 的潜力。</li>
<li>检查 Waterdrop 的收益增长报告，以了解分析师对其表现的预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis"/></p>
<p>WDH Financial Position Analysis as at Oct 2025</p>
<div class="lb-trans"><p>WDH 财务状况分析截至 2025 年 10 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Get an in-depth perspective on all 362 US Penny Stocks by using our screener here.</li>
<li>Searching for a Fresh Perspective? The end of cancer? These 28 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过在这里使用我们的筛选器，深入了解所有 362 只美国便士股票。</li>
<li>寻找新的视角？癌症的终结？这 28 只新兴 AI 股票正在开发技术，以便早期识别改变生命的疾病，如癌症和阿尔茨海默病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Rapid Micro Biosystems 和两个值得关注的有前景的便士股票